文献速递慢阻肺

慢性阻塞性肺疾病药物治疗与肺功能下降:系统综述

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该系统综述纳入9项安慰剂对照随机试验,共33,051例慢阻肺患者,评估持续≥1年的药物治疗对FEV1下降速率的影响。结果显示,活性治疗组FEV1年下降速率较安慰剂组减少5.0 ml/年(95%CI 0.8-9.1 ml/年;P<0.001)。作者认为药物治疗可改善肺功能下降速率,其相对获益与同一研究中健康状态和急性加重率的改善范围相当,建议据此调整指南。

要点

  • 长期药物治疗可减缓慢阻肺患者FEV1年下降速率约5.0 ml/年。
  • 该获益幅度与健康状态及急性加重率改善范围相当。
  • 建议根据此发现调整慢阻肺相关指南。

核心结论

  • 在慢阻肺患者中,药物治疗可改善肺功能下降速率。
  • 观察到的相对获益与同一研究中健康状态和急性加重率的报告范围相当。
  • 指南应根据这些发现进行调整。

研究设计与样本

  • 系统综述纳入随机对照试验,要求至少一个活性治疗组和一个安慰剂组,并包含重复肺功能检查。
  • 排除标准:研究持续时间<1年、肺功能测量<3次或每组<100例受试者。
  • 采用Jadad评分评估研究设计,并使用随机效应模型合并研究以考虑研究内和研究间变异。
  • 分析共纳入9项研究、33,051例患者,其中活性治疗组21,941例,安慰剂组11,110例。

主要发现

  • 活性治疗组FEV1下降速率较安慰剂组减少5.0 ml/年(95%CI 0.8-9.1 ml/年;P<0.001)。
  • 活性治疗组与安慰剂组之间的相对FEV1差异在健康状态和急性加重率报告差异范围内。

关键数值与推荐

  • 纳入标准:随机对照试验,包含重复肺功能检查,至少一个活性治疗组和一个安慰剂组,研究持续时间≥1年,肺功能测量≥3次,每组≥100例受试者。

临床怎么用

  • 对于慢阻肺患者,可考虑长期药物治疗以减缓FEV1下降速率。
  • 临床决策时应结合药物治疗对健康状态和急性加重率的已知获益。

局限性

  • 因药物治疗已改善健康状态、急性加重率和症状,完成旨在改变FEV1下降速率的长期安慰剂对照研究可能不符合伦理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Whether pharmacological therapy alters decline in FEV1 in chronic obstructive pulmonary disease remains controversial. Because pharmacotherapy improves health status, exacerbation rate, and symptoms, it may be unethical to complete placebo-controlled long-term studies aimed at modifying FEV1 decline.Objectives: We conducted a systematic review of placebo-controlled pharmacological trials lasting ≥1 year to address the question of whether therapy alters FEV1 decline.Methods: A literature search for randomized trials that included repeated spirometry with at least one active and one placebo arm was conducted. Articles were excluded if study duration was <1 year, <3 spirometric measurements, or <100 subjects per arm. Study design was assessed using the Jadad score. To combine studies and find the estimated effect, we used random effects methodology to account for both within-study and between-study variation.Measurements and Main Results: There were 33,051 patients in the analysis (active component, n = 21,941; placebo, n = 11,110 in nine studies). The active treatment arms demonstrated a 5.0 ml/yr reduction (95% confidence interval, 0.8-9.1 ml/yr; P < 0.001) in the rate of FEV1 decline compared with the placebo arms. The relative FEV1 differences between active and placebo arms were within the range of differences reported for health status and for the exacerbation rate in the same studies.Conclusions: In chronic obstructive pulmonary disease, pharmacotherapy ameliorates rate of lung function decline. The relative benefit observed is within the range of those reported for health status and exacerbations in the same studies. Guidelines should be adjusted according to these findings.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. Am J Respir Crit Care Med. 2021. PMID: 32966751. doi:10.1164/rccm.202005-1854OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。